Zhan et al., 2021 - Google Patents
Stem Cells in the Myelodysplastic SyndromesZhan et al., 2021
View HTML- Document ID
- 8133806036993952613
- Author
- Zhan D
- Park C
- Publication year
- Publication venue
- Frontiers in Aging
External Links
Snippet
The myelodysplastic syndromes (MDS) represent a group of clonal disorders characterized by ineffective hematopoiesis, resulting in peripheral cytopenias and frequent transformation to acute myeloid leukemia (AML). We and others have demonstrated that MDS arises in, and …
- 201000003793 myelodysplastic syndrome 0 title abstract description 238
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Trowbridge et al. | Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS | |
Mastio et al. | Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs | |
Shastri et al. | Stem and progenitor cell alterations in myelodysplastic syndromes | |
Kagoya et al. | Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity | |
Schinke et al. | IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells | |
Jacamo et al. | Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance | |
Lau et al. | Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses | |
CN110753755B (en) | T cell depletion state specific gene expression regulator and application thereof | |
WO2014190035A2 (en) | Compositions and methods for identification, assessment, prevention, and treatment of cancer using histone h3k27me2 biomarkers and modulators | |
Palam et al. | Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway | |
Mitchell et al. | Expression and splicing of Ikaros family members in murine and human thymocytes | |
Adema et al. | Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts | |
Zhan et al. | Stem Cells in the Myelodysplastic Syndromes | |
Cruz Cruz et al. | Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment | |
Lin et al. | Persistent DNA damage–induced NLRP12 improves hematopoietic stem cell function | |
Eglenen-Polat et al. | A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer | |
Joshi et al. | Leukemia stem cells in the pathogenesis, progression, and treatment of acute myeloid leukemia | |
Appelbaum | Acute leukemias in adults | |
Zhang et al. | Why single-cell sequencing has promise in MDS | |
Muraro et al. | KIR-HLA functional repertoire influences trastuzumab efficiency in patients with HER2-positive breast cancer | |
LeBlanc et al. | Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma | |
Flores et al. | Comparative analysis of Tet2 catalytic-deficient and knockout bone marrow over time | |
Bassani | Role of CD40 and Zeb1 in Shaping Normal and Leukemic Bone Marrow Niche | |
Sun | Investigating Anti-Leukemic Stem Cell Compounds | |
US20240262909A1 (en) | Tim-3 modulates anti-tumor immunity by regulating inflammasome activation |